There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...

According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD 27.71 billion by 2034, growing ...

Viral vector service expansion empowers scientists by offering high-quality research reagents through on-demand AAV production from Addgene’s vast plasmid repository Addgene, a purpose-driven ...

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, today announced a ...

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology ...

Learn how advances in stabilization, automation, and SR-DLS are making PEI-based transient transfection more efficient, ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its ...